Yuta Yamamoto

Saga, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Journal: Blood neoplasia
Published: April 18, 2025

Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.

Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.

Journal: International journal of molecular sciences
Published: October 04, 2024

DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.

DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.

Journal: Leukemia
Published: February 14, 2024

Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry.

Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry.

Journal: Acta histochemica et cytochemica
Published: September 01, 2023

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Journal: Blood advances
Published: July 05, 2023

Development of a specific and sensitive sandwich enzyme-linked immunosorbent assay for the quantification of dasatinib.

Development of a specific and sensitive sandwich enzyme-linked immunosorbent assay for the quantification of dasatinib.

Journal: Analytical biochemistry
Published: July 03, 2023

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

Journal: Cancers
Published: May 01, 2023

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

Journal: Cancer research communications
Published: July 01, 2022

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

Journal: Blood advances
Published: June 17, 2022

Development of a Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Sunitinib Unaffected by Light-Induced Isomerization.

Development of a Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Sunitinib Unaffected by Light-Induced Isomerization.

Journal: Biological & pharmaceutical bulletin
Published: October 04, 2021

Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

Journal: International journal of cancer
Published: August 12, 2021

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Journal: Cancer letters
Published: June 29, 2021
Showing 1-12 of 25

Last Updated: 09/26/2026